Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $6.12 USD
Change Today +0.23 / 3.90%
Volume 805.4K
CORT On Other Exchanges
As of 8:10 PM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

corcept therapeutics inc (CORT) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/9/15 - $6.65
52 Week Low
06/3/14 - $2.08
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

corcept therapeutics inc (CORT) Related Bloomberg News

View More Bloomberg News

corcept therapeutics inc (CORT) Related Businessweek News

No Related Businessweek News Found

corcept therapeutics inc (CORT) Details

Corcept Therapeutics Incorporated, a pharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of metabolic, oncologic, and psychiatric disorders in the United States. The company focuses on disorders that are associated with a steroid hormone called cortisol. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is also developing Korlym’s active ingredient, which is in a Phase 1/2 trial in combination with the chemotherapy drug eribulin (Halaven) to treat patients with GR-positive triple-negative breast cancer, a form of cancer with a particularly poor prognosis; and CORT 125134, a proprietary, selective GR antagonist that is in a Phase 1 clinical study to assess its safety, tolerability, and pharmacokinetics in healthy human volunteers. In addition, it discovers and develops three series of novel selective GR-II antagonists. The company has research and development agreements with Argenta Discovery Limited and Sygnature Discovery Limited. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.

50 Employees
Last Reported Date: 03/13/15
Founded in 1998

corcept therapeutics inc (CORT) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $571.3K
Chief Financial Officer and Secretary
Total Annual Compensation: $350.9K
Senior Vice President of Oncology
Total Annual Compensation: $397.4K
Chief Accounting Officer, Vice President and ...
Total Annual Compensation: $251.8K
Compensation as of Fiscal Year 2014.

corcept therapeutics inc (CORT) Key Developments

Corcept Therapeutics Incorporated Reaffirms Revenue Outlook for the Year 2015

Corcept Therapeutics Incorporated reaffirmed revenue outlook for the year 2015. For the period, the company’s reaffirmed its revenue guidance to be in the range of $47 million to $53 million.

Corcept Therapeutics Incorporated Announces Unaudited Earnings Results for the First Quarter Ended March 31, 2015

Corcept Therapeutics Incorporated announced unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported net revenues of $10,102,000 against $4,405,000 a year ago. Loss from operations was $4,030,000 against $12,859,000 a year ago. Net loss was $4,830,000 against $13,390,000 a year ago. Basic and diluted loss per share was $0.05 against $0.14 a year ago. Non-GAAP net loss was $2,659,000 against $11,508,000 a year ago. Non-GAAP basic and diluted net loss per share was $0.03 against $0.11 a year ago.

Corcept Therapeutics Incorporated to Report Q1, 2015 Results on May 07, 2015

Corcept Therapeutics Incorporated announced that they will report Q1, 2015 results on May 07, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CORT:US $6.12 USD +0.23

CORT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Novartis AG SFr.96.50 CHF -1.95
View Industry Companies

Industry Analysis


Industry Average

Valuation CORT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 19.3x
Price/Book 62.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 18.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CORCEPT THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at